Benzinga | Dec 10, 2021 07:55AM EST

Raymond James Downgrades Zymeworks to Outperform, Announces $74 Price Target

Raymond James analyst David Novak downgrades Zymeworks (NYSE:ZYME) from Strong Buy to Outperform and announces $74 price target.